History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study
276.0
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888, carboplatin, paclitaxel or other agents used in study
162.0
History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in study
107.0
Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study, including Cremophor, carboplatin, paclitaxel, cisplatin, 5-fluorouracil, hydroxyurea, or any compounds of similar chemical or biologic composition are not eligible
110.0
Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to dabrafenib or other agents used in this study including dimethyl sulfoxide (DMSO)
97.0
History of allergic reactions attributed to compounds of similar chemical or biologic composition to pomalidomide (e.g. lenalidomide, thalidomide) or other agents used in study
63.0
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ibrutinib or other agents used in study
52.0
History of allergic reactions attributed to compounds of similar chemical or biologic composition to cabozantinib, nivolumab, ipilimumab or other agents used in study
135.0
History of allergic reactions attributed to compounds of similar chemical or biologic composition to talazoparib (BMN 673) or other agents used in study
66.0
History of allergic reactions attributed to compounds of similar chemical or biologic composition to sEphB4-HSA or other agents used in study
42.0
History of allergic reactions attributed to compounds of similar chemical or biologic composition to ipilimumab, nivolumab, or other agents used in study, or history of severe hypersensitivity reaction to any monoclonal antibody
84.0
History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide and blinatumomab or other agents used in study
36.0
History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib or ganitumab or other agents used in study
24.0
History of allergic reactions attributed to compounds of similar chemical or biologic composition to selumetinib or other agents used in study
28.0
History of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study
60.0
History of allergic reaction attributed to compounds of similar or biologic composition to inotuzumab ozogamicin or other agents in the study
53.0
History of allergic reactions attributed to compounds of similar chemical or biological composition to other agents used in this study
78.0
